squalamine has been researched along with Parkinson Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amin, JY; Barbut, D; Bienenstock, J; Delungahawatta, T; Diwakarla, S; Farhin, S; Furness, JB; Kunze, WA; Mao, YK; McQuade, RM; Pustovit, R; Stanisz, AM; West, CL; Zasloff, M | 1 |
| Aprile, FA; Bax, A; Cascella, R; Cecchi, C; Challa, PK; Chen, SW; Chiti, F; Cohen, SI; Cremades, N; Dobson, CM; Flagmeier, P; Galvagnion, C; Heller, GT; Kirkegaard, JB; Knowles, TP; Limbocker, R; Maltsev, A; Meisl, G; Müller, MB; Nollen, EA; Perni, M; Sormanni, P; Vendruscolo, M; Zasloff, M | 1 |
2 other study(ies) available for squalamine and Parkinson Disease
| Article | Year |
|---|---|
Squalamine Restores the Function of the Enteric Nervous System in Mouse Models of Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Cholestanols; Constipation; Disease Models, Animal; Electrophysiological Phenomena; Enteric Nervous System; Gastrointestinal Motility; Jejunum; Mice; Mice, Transgenic; Mutant Proteins; Myenteric Plexus; Neurons, Afferent; Parkinson Disease; Patch-Clamp Techniques; Vagus Nerve | 2020 |
A natural product inhibits the initiation of α-synuclein aggregation and suppresses its toxicity.
Topics: Algorithms; alpha-Synuclein; Amino Acid Sequence; Animals; Animals, Genetically Modified; Biological Products; Caenorhabditis elegans; Cell Line, Tumor; Cholestanols; Humans; Membrane Lipids; Molecular Structure; Neuroblastoma; Paresis; Parkinson Disease; Protein Aggregates; Protein Aggregation, Pathological; Protein Binding; Protein Multimerization | 2017 |